NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Apr 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
ALORA (estradiol) by Teva is characteristics. Approved for menopause, contraception. First approved in 2002.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALORA is a transdermal extended-release estradiol film approved in 2002 for menopausal symptom management and contraception. It delivers estradiol, the most potent endogenous estrogen, through the skin to bind nuclear estrogen receptors and modulate gonadotropin secretion. The drug addresses the hormonal deficit in postmenopausal women by restoring circulating estrogen levels.
LOE Approaching
ALORA faces significant competitive pressure (30%) in a crowded estradiol market with LOE approaching, suggesting a shrinking brand team focused on retention rather than growth.
Mechanism of Action
characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in…
Indications (2)
Worked on ALORA at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.